Analysts have recommended buying shares of Metropolis Healthcare, Mahindra & Mahindra Ltd., Godrej Consumer Products Ltd., Ajanta Pharma Ltd., and Alkem Laboratories Ltd.
Rajesh Palviya, senior vice president, technical and derivatives research, at Axis Securities, Aditya Arora, founder and multi asset research analyst at Adlytick.in, and Shrikant Chouhan, head of equity research at Kotak Securities share their insights with NDTV Profit. These stock calls have the potential to generate upsides of up to 5%, according to them.
Mahindra & Mahindra
Chouhan recommends buying M&M for a target price of Rs 3,250 per share, implying 5% upside and keeping a stop loss of Rs 3,040. The stock fell for a second consecutive session on Monday after hitting its lifetime high on Friday. It has gained 88% in the last 12 months.
The company reported a 20% increase in total production, reaching 53,361 units in comparison to 44,495 units in the same period last year. Total sales saw a 14% rise, amounting to 66,676 units compared to 58,369 units YoY.
Metropolis Healthcare
Arora recommends buying Metropolis Healthcare for a target of Rs 2,140 per share, implying upside of 5% and keeping stop loss of Rs 1,960. The stock rose on Monday following three consecutive sessions of fall.
Metropolis Healthcare on Dec. 9 announced the acquisition of New Delhi-based Core Diagnostics at a cost of Rs 246.8 crore. Metropolis will acquire a 100% stake in Core Diagnostics through a combination of cash and stock, financing 55% of the transaction in cash and 45% through an equity swap.
Godrej Consumer
Arora has also recommended a 'buy' on Godrej Consumer for a target of Rs 1,190 per share, implying 4.7% upside. It has kept a stop loss of Rs 1,102. The stock has risen consecutively in last three sessions. In the last 12 months, it has fallen 2%.
Goldman Sachs said that peak of cyclical headwinds from palm oil and adverse seasonality are likely behind post third quarter. The brokerage expects a recovery starting fourth quarter. It maintained its 'buy' call on the stock with a target of Rs 1,370.00 per share, implying an upside of 25.3%
Ajanta Pharma
Arora recommends buying shares of Ajanta Pharma for a target of Rs 3,047, implying 3.3% upside and a stop loss of Rs 2,847 per share. It snapped its two-day fall on Monday and has risen 35.55% in the last 12 months.
Alkem Labs
Palviya recommends buying Alkem Laboratories for a target of Rs 5,610 per share, implying 1.5% upside and he has kept stop loss of Rs 5,465. The stock hit its one-month high on Dec. 9. It has risen 10% in the last 12 months.
On Wednesday it said it has received income tax orders worth Rs 375 crore for the assessment years 2020-21 and 2022-23.
Disclaimer: The views and opinions expressed by the investment advisers on NDTV Profit are of their own and not of NDTV Profit. NDTV Profit advises users to consult with their own financial or investment adviser before taking any investment decision.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
